NDAORALCAPSULEPriority Review
Approved
Feb 2022
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
7
Mechanism of Action
Tyrosine Kinase Inhibitors
Pharmacologic Class:
Kinase Inhibitor
Clinical Trials (5)
Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias
Started May 2026
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Started Mar 2026
27 enrolled
Accelerated Phase Myeloproliferative NeoplasmBlast Phase Myeloproliferative Neoplasm
Pacritinib For Bone Marrow Fibrosis In Patients With Myelofibrosis Who Have Thrombocytopenia
Started Mar 2026
30 enrolled
Myelofibrosis，MF
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Started May 2025
78 enrolled
VEXASVEXAS Syndrome
Pacritinib in Vacuoles, E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic (VEXAS) Syndrome
Started Feb 2025
15 enrolled
E1 Ubiqutin-activating Enzyme, X-linked, Autoinflammatory, Somatic SyndromeVEXASVexas Syndrome
Loss of Exclusivity
LOE Date
Mar 25, 2030
49 months away
Patent Expiry
Mar 25, 2030
Exclusivity Expiry
Feb 28, 2029